Heartflow (HTFL) investor relations material

Executive summary

• Q3 revenue was $72.9M, up 57.4% YoY; growth accelerated for a third consecutive quarter, driven primarily by higher U.S. FFRct and Plaque Analysis case volumes.

• Revenue cases reached 98,155, up 89.5% YoY; the platform had assessed more than 800,000 patients by September 30, 2026.

• FY26 revenue and non-GAAP gross margin guidance increased amid stronger platform performance, expanding clinical evidence and CCTA market adoption.

Financial highlights

• Q3 revenue was $72.9M versus $46.3M YoY; nine-month revenue was $189.5M versus $126.9M.

• U.S. revenue was $67.9M, up 60% YoY, including $11.8M from Plaque Analysis; international and other revenue was $4.9M.

• Gross profit was $60.9M versus $35.4M; GAAP gross margin was 83.6% versus 76.5%, and non-GAAP gross margin was 83.8% versus 76.8%.

• GAAP net loss was $11.5M, or $0.13/share, versus $50.9M, or $1.04/share; non-GAAP net loss was $2.7M, or $0.03/share.

• Non-GAAP operating loss narrowed to $5.0M from $11.1M; adjusted EBITDA loss was $3.6M versus $9.8M.

Outlook and guidance

• FY26 revenue guidance rose to $262M–$264M, or 49%–50% YoY growth, from prior guidance of $246M–$250M.

• FY26 Plaque Analysis revenue guidance increased to $36M–$37M; year-end plaque-enabled accounts are expected to reach 1,300.

• FY26 non-GAAP gross margin guidance increased to ~82.5%; non-GAAP OpEx as a share of revenue is expected to decline by more than five points.

• Management targets cash flow profitability by mid-2028 and maintains an 85% midterm non-GAAP gross margin target.

• Q4 guidance includes typical holiday seasonality, implies nearly 37% YoY FFRct volume growth, and assumes Plaque pricing roughly flat sequentially.